Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Alumis (NASDAQ:ALMS) with a Buy and maintains $14 price target.
Alumis (NASDAQ:ALMS) reported quarterly sales of $2.67 million which beat the analyst consensus estimate of $2.00 million by 33...
Wells Fargo analyst Derek Archila initiates coverage on Alumis (NASDAQ:ALMS) with a Overweight rating and announces Price Ta...
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Alumis (NASDAQ:ALMS) with a Buy and maintains $14 price target.
Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immun...
- SEC Filing
Guggenheim analyst Yatin Suneja reinstates Alumis (NASDAQ:ALMS) with a Buy and announces $18 price target.
